BioMarin Raises $850 Million in Debut Bond Offering to Finance Amicus Therapeutics Acquisition
Key Insights
BioMarin Pharmaceutical completed its first-ever senior notes offering, raising $850 million through 5.500% senior notes due 2034 to support strategic expansion.
The proceeds will finance BioMarin's acquisition of Amicus Therapeutics and debt repayment, combining two rare disease (search)-focused biotechnology companies.
This transaction represents a significant consolidation move in the rare disease (search) therapeutics sector, bringing together over 25 years of BioMarin's pioneering experience with Amicus's complementary portfolio.
BioMarin Pharmaceutical Inc. successfully completed its inaugural senior notes offering, raising $850 million through 5.500% senior notes due 2034 in a Rule 144A/Regulation S transaction. The San Rafael, California-based rare disease (search) biotechnology company will use the net proceeds, combined with cash on hand and expected borrowings under a new term loan facility, to finance its acquisition of Amicus Therapeutics, Inc. and repay the acquired company's existing debt.
Strategic Acquisition in Rare Disease Space
The bond offering represents a pivotal financing move for BioMarin as it expands its rare disease (search) portfolio through the Amicus acquisition. BioMarin has established itself as a leading global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions (search). For over 25 years, the company has pioneered the development of therapies to treat rare conditions, consistently addressing unmet medical needs across multiple rare diseases.
Financial Structure and Market Position
The debut senior notes offering marks BioMarin's entry into the corporate bond market, utilizing a combination of debt financing strategies to fund the strategic acquisition. The 5.500% coupon rate on the 10-year notes reflects current market conditions for biotechnology debt offerings. The transaction structure includes both Rule 144A and Regulation S components, providing access to both institutional and international investor bases.
Industry Consolidation Trend
This acquisition financing represents part of a broader consolidation trend in the rare disease (search) therapeutics sector, where specialized biotechnology companies are combining resources and expertise to enhance their ability to serve patients with genetically defined conditions (search). The combination of BioMarin's established rare disease platform with Amicus Therapeutics' portfolio is expected to create synergies in research, development, and commercialization capabilities.
The transaction underscores the capital-intensive nature of rare disease (search) drug development and the strategic importance of scale in addressing the complex challenges of bringing therapies to patients with limited treatment options.